Overview
The healthcare sector is entering a new era of personalised medicine in which clinicians are increasingly able to offer more individualised diagnosis and characterisation of many diseases, including cancer, epilepsy and stroke.

Researchers and clinicians are also developing new therapies using new information about the genetic basis and cell biology of particular disease conditions that benefit from imaging as a means for assessing therapeutic effects.

Advances in the understanding of disease causation requires tracers with high specificity for functional imaging and high spatial, temporal and energy resolution for traditional x-ray imaging. As the “tree of disease causation" is climbed, signal strength declines and ever more sensitive detection methods are required.


The CRC's research outcomes
Research conducted by the CRC for Biomedical Imaging Development Ltd (CRC BID) is aimed at achieving substantial advances in radiotracer diagnosis and studies of cancer and neurodegenerative conditions.

The CRC's participants are developing new, highly-specific radiotracers, automated processes for on-site synthesis of radiotracers (and other radiopharmaceuticals), and high-resolution detectors for functional (PET) and structural (X-ray) imaging.

All research projects undertaken by CRC BID are linked to commercial outcomes and will contribute to national research priorities particularly related to human health for radiopharmaceutical projects and frontier technologies for detector projects.


> Go to Research Projects